Sarepta Therapeutics Faces Class Action Lawsuit Over ELEVIDYS Gene Therapy

Strategic Insights -

Shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) who suffered losses due to alleged securities fraud have a chance to seek recovery. A class action lawsuit was filed against the company, alleging that it made false statements and concealed the safety risks associated with its ELEVIDYS gene therapy for Duchenne. The complaint claims that the company's trial regimes and protocols failed to detect severe side effects, which led to regulatory scrutiny and increased risk around the therapy's approvals. Shareholders who were adversely affected by these alleged actions between June 22, 2023, and June 24, 2025, may be eligible to participate in the lawsuit.

Key Takeaways:

  • Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is facing a class action lawsuit over its ELEVIDYS gene therapy for Duchenne.
  • The complaint alleges that the company made false statements and concealed safety risks associated with ELEVIDYS.
  • Shareholders who suffered losses between June 22, 2023, and June 24, 2025, may be eligible to participate in the lawsuit.
  • Levi & Korsinsky LLP is representing the plaintiffs, citing extensive expertise in complex securities litigation.
  • The firm has a track record of securing hundreds of millions of dollars for aggrieved shareholders and has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Statistics:

  • The lawsuit was filed against Sarepta Therapeutics, Inc. between June 22, 2023, and June 24, 2025.
  • The complaint alleges that the company's trial regimes and protocols failed to detect severe side effects from ELEVIDYS treatment.
  • Levi & Korsinsky LLP has secured hundreds of millions of dollars for aggrieved investors in complex securities litigation.

Sources:

  • Newsfile Corp (August 15, 2025)
  • Levi & Korsinsky, LLP (contact information provided)
  • ISS Securities Class Action Services (ranking report)
  • Levi & Korsinsky, LLP (press release and contact information)